All In Biotech

Drug Trial Radar · NCT04114825

Study of RV001V in Biochemical Failure Following Curatively Intended Therapy For Localized Prostate Cancer

A Phase 2, Double-Blind, Placebo Controlled Study of RV001V in Men With Biochemical Failure Following Curatively Intended Therapy For Localized Prostate Cancer (BRaVac)

Last checked: Nov 19, 2026Latest source record: Sep 28, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 180 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

180

Planned (sponsor's estimate)

Start

Nov 19, 2019

Primary completion

Apr 2022

Study completion Nov 2022

Sponsor

Lead sponsor
RhoVac APSIndustry
Sponsor type
Industry
First posted
Oct 3, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase II trial will enroll approximately 180 adult male patients with an earlier histologic diagnosis of prostatic adenocarcinoma and a biochemical recurrence (BCR) within 3 years of radical prostatectomy (RP) or definitive RT and no distant metastasis or locoregional recurrence. The trial is a randomized placebo-controlled double-blind study of a peptide cancer vaccine (RV001V).

Conditions

  • Prostate Cancer Recurrent

Interventions

  • RV001VBiological

    RV001V consists of the peptide RV001 and the adjuvant Montanide ISA 51. RV001 Vaccine 0.1 mg/mL (RV001V).

  • PlaceboOther

    Placebo consist of the vaccine vehicle and the adjuvant Montanide ISA 51. Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to PSA progressionTime frame: Up to 3 years

Locations

36 sites in 7 countries. Site status is shown where the registry gives one.

  • Tampa Bay Medical Research

    Clearwater, Florida

  • Chesapeake Urology Research Associates

    Towson, Maryland

  • GU Research Network/Urology Cancer Center

    Omaha, Nebraska

  • Comprehensive Cancer Centers of Nevada

    Las Vegas, Nevada

  • Icahn School of Medicine at Mount Sinai Hospitals

    New York, New York

  • Carolina Urologic Research Center

    Myrtle Beach, South Carolina

  • The Urology Place

    San Antonio, Texas

  • Gent University Hospital

    Ghent, Belgium

  • CHU de Liège

    Liège, Belgium

  • Hôpital Erasme

    Liège, Belgium

  • Aalborg University, Departmen of Urology

    Aalborg, Denmark

  • Aarhus University Hospital, Department of Urology

    Aarhus, Denmark

  • Rigshospitalet, Copenhagen Prostate Cancer Center

    Copenhagen, Denmark

  • Herlev & Gentofte Hospital, Department of Urology

    Herlev, Denmark

  • Urinvejskirurgisk afdeling, Hospitalsenheden Vest

    Holstebro, Denmark

  • Odense University Hospital, Deparment of Urology

    Odense, Denmark

  • Meilahti Tower Hospital

    Helsinki, Finland

  • Oulu University Hospital

    Oulu, Finland

  • Seinajoki Central Hospital

    Seinäjoki, Finland

  • Tampere University Hospital

    Tampere, Finland

  • Turku University Hospital

    Turku, Finland

  • University Hospital Dresden

    Dresden, Germany

  • Urologicum Duisburg

    Duisburg, Germany

  • Urologische Praxis Dr. Wolfgang Warnack

    Hagenow, Germany

  • Urologische Praxis. M. Markov

    Halle, Germany

  • Studienpraxis Urologie

    Nürtingen, Germany

  • University Hospital Tuebingen

    Tübingen, Germany

  • Sahlgrenska University Hospital

    Gothenburg, Sweden

  • Skåne University Hospital

    Malmö, Sweden

  • Örebro University Hospital

    Örebro, Sweden

  • Karolinska University Hospital

    Stockholm, Sweden

  • Umeå University Hospital

    Umeå, Sweden

  • Clatterbridge Centre for Oncology

    Liverpool, United Kingdom

  • Royal Free London NHS Foundation Trust Royal Free Hospital

    London, United Kingdom

  • Nottingham University Hospital

    Nottingham, United Kingdom

  • University Hospital Southampton

    Southampton, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.